MADISON, Wis., Aug. 21, 2023 /PRNewswire/ -- With an alarming rise in colorectal cancer (CRC) among younger people, new research shines light on the beliefs, behaviors and barriers standing in the way of 45-year-olds in the United States completing potentially lifesaving CRC screenings.2,3 Exact Sciences, a leading provider of cancer screening and diagnostic tests, convened a steering committee of national experts to design and field the "I Am 45" poll, the most robust survey ever of 45-year-olds in the United States about cancer screening (n=1,005).
"Colorectal cancer is one of the deadliest, but also one of the most preventable cancers, and routine screening starting at age 45 using one of several guideline-recommended methods is the most effective way to reduce risk of dying from this disease," said Cynthia M. Yoshida, MD, a gastroenterologist at the University of Virginia Medical Center and medical lead of the UVA Comprehensive Cancer Center's Colorectal Cancer Screening Program. "Despite this, we see many people in this critical age group not getting screened, and this research provides an important but troubling window into why, revealing not just one, but a multitude of barriers – a virtual obstacle course to lifesaving colorectal cancer screening."
Findings revealed that there are countless reasons why 45-year-olds are not getting screened:3
In partnership with The Harris Poll, the nationwide study questioned more than 1,000 45-year-olds – the national guideline-recommended age to start screening for colorectal cancer1 – on a number of topics that impact their mindset and behaviors around health, and more specifically, CRC screening. Three out of four (76%) 45-year-olds indicated that there was at least one reason they would delay or avoid CRC screening, possibly explaining why many have not been screened and suggesting the few who did report being screened by colonoscopy (21%) and/or a test that could be used at home (14%) may have had to navigate these challenges to do so.3
It is estimated that nationwide implementation of an 80% colorectal cancer screening prevalence for all eligible adults could save tens of thousands of lives by preventing numerous cases and deaths.4 For individuals younger than 50, colorectal cancer incidence rates and later-stage diagnoses are rising at alarming rates. In 2023, an estimated 19,550 individuals under 50 will be diagnosed with colorectal cancer, and 3,750 will die from this cancer.2,4 This disease disproportionately affects different socioeconomic groups, races and regions in the United States, with higher rates being observed in certain communities such as Black and American Indian or Alaska Native communities.2,4
"The 'I Am 45' poll helps us understand colorectal cancer screening disparities as well as the lack of awareness due to the multitude of barriers across the most at-risk populations, and importantly on a more relational and culturally competent level," said Natalie Donnally, Vice President, African American Male Wellness Agency.
By design, the poll segmented the data across gender, race and region, providing insights to inform tailored solutions that can help address barriers unique to different communities, and ultimately impact low screening rates for colorectal cancer.
Key findings from the "I Am 45" poll identified the following barriers to CRC screening:3
The steering committee that designed the "I Am 45" poll is committed to working to address these potential barriers to improve CRC screening rates and urges 45-year-old Americans to talk with their healthcare providers about selecting and completing the CRC screening test most appropriate for them. The committee will utilize the learnings from the survey to build and enhance programs intended to increase screening for colorectal cancer.
"In convening this steering committee and commissioning the 'I Am 45' poll, it was our goal to uncover opportunities to identify key barriers to timely, regular colorectal cancer screening to better meet the needs of this younger population," said Paul Limburg, Chief Medical Officer, Screening at Exact Sciences. "From this research, we learned that one in three (33%) 45-year-olds do not currently realize that screening can prevent colorectal cancer in some patients, showing that more work is needed to raise awareness and motivate action. We are committed to continuing education efforts to address this knowledge gap and working with our steering committee members to find creative solutions for increasing screening engagement for eligible patients who are under age 50."
About the "I Am 45" Poll
The "I Am 45" poll was conducted online in the United States by The Harris Poll on behalf of Exact Sciences among 1,005 adults aged 45 years. Data collection was conducted March 6-14, 2023. For complete research methodology, including weighting variables, credible interval and subgroup sample sizes, please contact Lindsey Dickinson at This email address is being protected from spambots. You need JavaScript enabled to view it..
About the "I Am 45" Steering Committee
The steering committee that designed the "I Am 45" poll is comprised of national experts in colorectal cancer and the broader health space to provide expert insight into areas of exploration for the survey. The members of this committee include executives and thought leaders from the following organizations: African American Male Wellness Agency, American Cancer Society, American Gastroenterological Association, Colorectal Cancer Alliance, Jefferson Einstein Montgomery, Fight Colorectal Cancer, National Minority Quality Forum and the University of Michigan Center for Value-Based Insurance Design.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
References:
Media (U.S.):
Lindsey Dickinson
+1 608-690-0383
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Megan Jones
+1 608-535-8815
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$61.69 |
Daily Change: | 1.59 2.65 |
Daily Volume: | 2,472,883 |
Market Cap: | US$11.400B |
November 25, 2024 November 13, 2024 November 05, 2024 October 27, 2024 October 04, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB